

PRODUCT INFORMATION



LAG-3 Extracellular Domain (human, recombinant)


Item No. 32083

Overview and Properties

Synonyms: CD223, Lymphocyte Activation Gene 3 Protein
Source: Recombinant human C-terminal His-tagged LAG-3 expressed in HEK293 cells
Amino Acids: 29-450
Uniprot No.: P18627
Molecular Weight: 47 kDa
Storage: -80°C (as supplied)
Stability: ≥1 year
Purity: ≥95% estimated by SDS-PAGE
Supplied in: Lyophilized from sterile PBS, pH 7.4
Endotoxin Testing: <1.0 EU/μg, determined by the LAL endotoxin assay

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Lane 1: MW Markers
Lane 2: LAG-3 Extracellular Domain

SDS-PAGE Analysis of LAG-3 Extracellular Domain. This protein has a calculated molecular weight of 47 kDa. It has an apparent molecular weight of approximately 50-60 kDa by SDS-PAGE under reducing conditions due to glycosylation.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/21/2023

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Lymphocyte activation gene 3 (LAG-3) protein is a CD4-like protein and member of the immunoglobulin superfamily (IgSF) that binds with high affinity to MHC class II molecules.^{1,2} LAG3 is expressed in activated T cells and natural killer cells, and the protein functions as an inhibitory co-receptor that modulates T cell homeostasis, proliferation, expansion, activation, and function.²⁻⁴ LAG-3 is comprised of an N-terminal extracellular domain with four IgSF domains, a transmembrane domain, and a C-terminal cytoplasmic domain with a KIEELE motif required for modulation of T cell function.¹⁻³ Elevated LAG3 expression in chronic lymphocytic leukemia (CLL) cells is associated with reduced treatment-free survival in patients with CLL.⁵ Co-administration of antibodies against both LAG-3 and PD-1 reduces the number and percentage of CLL cells in blood and spleen in a CLL-splenocyte adoptive transfer mouse model.⁶ SNPs in LAG3 are associated with susceptibility to multiple sclerosis.⁷ Cayman's LAG-3 Extracellular Domain (human, recombinant) protein consists of 433 amino acids, has a calculated molecular weight of 47 kDa, and a predicted N-terminus of Val29 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 50 to 60 kDa due to glycosylation.

References

1. Baixeras, E., Huard, B., Miossec, C., *et al.* Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. *J. Exp. Med.* **176(2)**, 327-337 (1992).
2. Goldberg, M.V. and Drake, C.G. LAG-3 in cancer immunotherapy. *Cancer Immunology and Immunotherapy*. Dranoff, G., editor, *Springer* (2011).
3. Triebel, F., Jitsukawa, S., Baixeras, E., *et al.* LAG-3, a novel lymphocyte activation gene closely related to CD4. *J. Exp. Med.* **171(5)**, 1393-1405 (1990).
4. Siero, S., Romero, P., and Speiser, D.E. The CD4-like molecule LAG-3, biology and therapeutic applications. *Expert. Opin. Ther. Targets* **15(1)**, 91-101 (2011).
5. Kotaskova, J., Tichy, B., Trbusek, M., *et al.* High expression of *lymphocyte-activation gene 3* (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated *immunoglobulin variable heavy chain region* (IGHV) gene and reduced treatment-free survival. *J. Mol. Diagn.* **12(3)**, 328-334 (2010).
6. Wierz, M., Pierson, S., Guyonnet, L., *et al.* Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. *Blood* **131(14)**, 1617-1621 (2018).
7. Zhang, Z., Duvefelt, K., Svensson, F., *et al.* Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. *Genes Immun.* **6(2)**, 145-152 (2005).